2fuc: Difference between revisions

New page: left|200px<br /> <applet load="2fuc" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fuc, resolution 2.10Å" /> '''Human alpha-Phospho...
 
No edit summary
Line 1: Line 1:
[[Image:2fuc.gif|left|200px]]<br />
[[Image:2fuc.gif|left|200px]]<br /><applet load="2fuc" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2fuc" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2fuc, resolution 2.10&Aring;" />
caption="2fuc, resolution 2.10&Aring;" />
'''Human alpha-Phosphomannomutase 1 with Mg2+ cofactor bound'''<br />
'''Human alpha-Phosphomannomutase 1 with Mg2+ cofactor bound'''<br />


==Overview==
==Overview==
Congenital disorder of glycosylation type 1a (CDG-1a) is a congenital, disease characterized by severe defects in nervous system development. It, is caused by mutations in alpha-phosphomannomutase (of which there are two, isozymes, alpha-PMM1 and alpha-PPM2). Here we report the x-ray crystal, structures of human alpha-PMM1 in the open conformation, with and without, the bound substrate, alpha-D-mannose 1-phosphate. Alpha-PMM1, like most, haloalkanoic acid dehalogenase superfamily (HADSF) members, consists of, two domains, the cap and core, which open to bind substrate and then close, to provide a solvent-exclusive environment for catalysis. The substrate, phosphate group is observed at a positively charged site of the cap, domain, rather than at the core domain phosphoryl-transfer site defined by, the Asp(19) nucleophile and Mg(2+) cofactor. This suggests that substrate, binds first to the cap and then is swept into the active site upon cap, closure. The orientation of the acid/base residue Asp(21) suggests that, alpha-phosphomannomutase (alpha-PMM) uses a different method of protecting, the aspartylphosphate from hydrolysis than the HADSF member, beta-phosphoglucomutase. It is hypothesized that the electrostatic, repulsion of positive charges at the interface of the cap and core domains, stabilizes alpha-PMM1 in the open conformation and that the negatively, charged substrate binds to the cap, thereby facilitating its closure over, the core domain. The two isozymes, alpha-PMM1 and alpha-PMM2, are shown to, have a conserved active-site structure and to display similar kinetic, properties. Analysis of the known mutation sites in the context of the, structures reveals the genotype-phenotype relationship underlying CDG-1a.
Congenital disorder of glycosylation type 1a (CDG-1a) is a congenital disease characterized by severe defects in nervous system development. It is caused by mutations in alpha-phosphomannomutase (of which there are two isozymes, alpha-PMM1 and alpha-PPM2). Here we report the x-ray crystal structures of human alpha-PMM1 in the open conformation, with and without the bound substrate, alpha-D-mannose 1-phosphate. Alpha-PMM1, like most haloalkanoic acid dehalogenase superfamily (HADSF) members, consists of two domains, the cap and core, which open to bind substrate and then close to provide a solvent-exclusive environment for catalysis. The substrate phosphate group is observed at a positively charged site of the cap domain, rather than at the core domain phosphoryl-transfer site defined by the Asp(19) nucleophile and Mg(2+) cofactor. This suggests that substrate binds first to the cap and then is swept into the active site upon cap closure. The orientation of the acid/base residue Asp(21) suggests that alpha-phosphomannomutase (alpha-PMM) uses a different method of protecting the aspartylphosphate from hydrolysis than the HADSF member beta-phosphoglucomutase. It is hypothesized that the electrostatic repulsion of positive charges at the interface of the cap and core domains stabilizes alpha-PMM1 in the open conformation and that the negatively charged substrate binds to the cap, thereby facilitating its closure over the core domain. The two isozymes, alpha-PMM1 and alpha-PMM2, are shown to have a conserved active-site structure and to display similar kinetic properties. Analysis of the known mutation sites in the context of the structures reveals the genotype-phenotype relationship underlying CDG-1a.


==About this Structure==
==About this Structure==
2FUC is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with MG as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Phosphomannomutase Phosphomannomutase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=5.4.2.8 5.4.2.8] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2FUC OCA].  
2FUC is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=MG:'>MG</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Phosphomannomutase Phosphomannomutase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=5.4.2.8 5.4.2.8] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FUC OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Phosphomannomutase]]
[[Category: Phosphomannomutase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Allen, K.N.]]
[[Category: Allen, K N.]]
[[Category: Dunaway-Mariano, D.]]
[[Category: Dunaway-Mariano, D.]]
[[Category: Lu, Z.]]
[[Category: Lu, Z.]]
[[Category: Silvaggi, N.R.]]
[[Category: Silvaggi, N R.]]
[[Category: Zhang, C.]]
[[Category: Zhang, C.]]
[[Category: MG]]
[[Category: MG]]
Line 26: Line 25:
[[Category: protein glycosylation]]
[[Category: protein glycosylation]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:10:22 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:25:15 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA